CClinicalTrials.gg
Not yet recruitingNCT07739680Updated Aug 4, 2026

Effects of Hippotherapy in Children With Cerebral Palsy

An interventional study of Hippotherapy Program and Special Education Program in Cerebral Palsy, Congenital, sponsored by Fenerbahce University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 7 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Fenerbahce University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
7 Years to 15 Years
Sex
All
01

Study summary

Cerebral palsy is a group of permanent disorders affecting movement and posture due to non-progressive disturbances in the developing brain. The aim of this study is to investigate the effects of hippotherapy on physical function, including balance, trunk control, posture, and handgrip strength, as well as bladder and bowel symptoms and family quality of life in children with cerebral palsy.

Read the detailed description

Cerebral palsy is a group of permanent disorders of movement and posture caused by non-progressive disturbances in the developing brain. Children with cerebral palsy may experience limitations in balance, trunk control, posture, mobility, and daily activities.

During hippotherapy, the rhythmic and multidirectional movements of the horse provide continuous sensory and motor stimulation, requiring the child to make repeated postural adjustments. These characteristics may support balance, postural control, muscle activation, and functional performance.

Although the effects of hippotherapy on motor function in children with cerebral palsy have been investigated, evidence regarding its combined effects on physical function, bladder and bowel symptoms, and family quality of life remains limited. Therefore, the present study aims to investigate the effects of hippotherapy on physical function-including balance, trunk control, posture, and handgrip strength-as well as bladder and bowel symptoms and family quality of life in children with cerebral palsy. The findings may contribute to the literature and provide guidance for rehabilitation practices.

02

Conditions studied

  • Cerebral Palsy, Congenital

Keywords

  • Cerebral Palsy
  • Children
  • Hippotherapy
  • Physical function
  • Postural balance
  • Bladder and bowel dysfunction
  • Hand grip strength
  • Trunk control
  • Quality of life
03

Who can participate

Ages eligible
7 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged between 7 and 15 years
  • Diagnosis of cerebral palsy confirmed by a specialist physician
  • Gross Motor Function Classification System (GMFCS) level I-III
  • Ability to understand and follow basic verbal commands
  • Ability to stand independently for at least 30 seconds
  • No medical contraindications to participation in hippotherapy
  • Voluntary participation in the study and written informed consent provided by a parent or legal representative

Exclusion criteria

Exclusion Criteria:

  • Presence of an active infection
  • Bladder or bowel symptoms caused by an organic condition, such as -Hirschsprung disease or anorectal malformation
  • Receipt of hippotherapy within the previous 12 months
  • Uncontrolled epilepsy or a seizure within the previous 6 months
  • Inability to comply with the assessment or treatment program because of severe behavioral problems
  • Inability to attend the treatment program regularly
  • Surgery affecting the spine, pelvis, or lower extremities within the previous 12 months
  • Severe hip dislocation, atlantoaxial instability, uncontrolled scoliosis, or another orthopedic condition constituting a contraindication to hippotherapy
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Hippotherapy Group

    Other: Hippotherapy Program

  • Active comparator
    Control Group

    Other: Special Education Program

Interventions

  • OtherHippotherapy Program

    Participants will receive 30-minute hippotherapy sessions once weekly for 8 weeks in addition to their ongoing special education program. The program will include exercises targeting balance, postural control, trunk stabilization, coordination, muscle strength, upper extremity function, and sensory processing.

  • OtherSpecial Education Program

    Participants will continue their ongoing special education program throughout the 8-week study period. The program includes educational activities, speech and language therapy, occupational therapy, proprioceptive activities, and sensory-based interventions according to the individual needs of the child.

05

What researchers measure

Primary outcomes

  1. Balance

    Balance will be assessed using the Pediatric Balance Scale, a 14-item scale evaluating sitting balance, standing balance, transfers, reaching, turning, and stepping activities. The total score ranges from 0 to 56, with higher scores indicating better balance performance. The scale will be administered by a physiotherapist.

    Time frame: Baseline and at the end of the 8-week intervention

  2. Trunk Control

    Trunk control will be assessed using the Trunk Control Measurement Scale. The total score ranges from 0 to 58, with higher scores indicating better trunk control. The assessment will be administered by a physiotherapist.

    Time frame: Baseline and at the end of the 8-week intervention

  3. Posture

    Postural alignment will be assessed using the New York Posture Rating Chart. The total score ranges from 13 to 65, with higher scores indicating better postural alignment. The assessment will be performed by a physiotherapist.

    Time frame: Baseline and at the end of the 8-week intervention

  4. Handgrip Strength

    Handgrip strength will be measured in kilograms using a hand dynamometer. Three measurements will be obtained for each hand, with a 1-minute rest period between measurements. The mean value of the three measurements will be used in the analysis. Higher values indicate greater handgrip strength.

    Time frame: Baseline and at the end of the 8-week intervention

  5. Bladder and Bowel Symptoms

    Bladder and bowel symptoms will be assessed using the Bladder and Bowel Dysfunction Questionnaire. The total score ranges from 0 to 52, with higher scores indicating greater symptom severity. The questionnaire will be completed by the child with parental assistance.

    Time frame: Baseline and at the end of the 8-week intervention

  6. Familiy Quality of Life

    Family quality of life will be assessed using the Cerebral Palsy Quality of Life Questionnaire-Primary Caregiver Form (CP QOL-Child). Each domain is scored from 0 to 100, with higher scores indicating better quality of life. The questionnaire will be completed by the child's parent or primary caregiver.

    Time frame: Baseline and at the end of the 8-week intervention

06

Study locations

1 site
  • Ankara Yildirim Beyazit University
    Ankara, Turkey (Türkiye)
    • General Secretariat · Contact · gensek@aybu.edu.tr · +90 312 906 2000
    • Seyda Toprak Celenay, PhD · Principal investigator
    • Elif Sena Dusgun, PhD · Sub investigator
    • Tugba Kilickaya, BSc · Sub investigator
    • Rumeysa Karayel, BSc · Sub investigator
07

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because the current ethics approval and informed consent procedures do not include sharing data with external researchers. In addition, the study involves a vulnerable pediatric population. Only aggregated and de-identified study results will be reported.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07739680
Lead sponsor
Fenerbahce University
Responsible party
Elif Sena Düşgün (Assistant Professor, Fenerbahce University) — Principal investigator
First posted
Jul 31, 2026
Start date
Aug 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 4, 2026

Study contacts

Seyda Toprak Celenay, PhD
Contact
sydtoprak@hotmail.com
+90 312 906 2000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion